News

Expert Suggests Changes in Fungus Treatment


 

LAS VEGAS – Competition among large retailers is bringing down the cost of terbinafine, but griseofulvin is still better for many fungal infections, according to Dr. Lawrence F. Eichenfield.

The ideal prescription depends on the type of fungus and the site of the infection, said Dr. Eichenfield, chief of pediatric and adolescent dermatology at the University of California, San Diego, at the pediatric update sponsored by the American Academy of Pediatrics California Chapter 9. Topical medications alone can seldom cure tinea capitis because the fungus finds protection inside hair follicles, but he advised using them in combination with systemic drugs.

The signs of tinea capitis include scaling, pustules, kerion, black dots, alopecia, adenopathy, and autoeczematization (also known as id reaction). The condition can resemble seborrheic dermatitis, psoriasis, folliculitis, and other diseases. “So it's worth doing a routine culture,” said Dr. Eichenfield, adding that it's fairly easy to obtain a specimen with a toothbrush, cotton swabs, or bacterial culturettes.

The most common culprit is Trichophyton tonsurans, which is spread by human contact. The second most common cause is Microsporum canis, which is spread by cats.

Family coinfection can contribute to treatment failure, so inquire about tinea capitis and tinea corporis in other affected family members and pets, said Dr. Eichenfield. The standard therapy for tinea capitis is microsized griseofulvin (20 mg/kg) for 6-8 weeks, he advised.

The only other approved drug is terbinafine granules, and these are hard to obtain, he said, but itraconazole and fluconazole might also work.

Particularly if griseofulvin fails, Dr. Eichenfield recommended terbinafine 4-8 mg/kg per day for 4 weeks. But one recent study found that griseofulvin was much better than terbinafine for M. canis (J. Am. Acad. Dermatol. 2008;59:41-54).

The same organisms, along with T. rubrum and T. mentagrophytes, can cause tinea corporis. Patients present with red scaling plaque, often with an active border. Central clearing may give the lesions a ring shape.

They can be treated with a wide variety of topical drugs, among them clotrimazole, econazole, oxiconazole, ciclopirox, terbinafine, and ketoconazole. Systemic treatment should be reserved for extensive disease or special circumstances, such as for wrestlers. The best systemic treatment is griseofulvin, 15-20 mg/kg (5-10 mg/kg ultramicrosize), said Dr. Eichenfield.

Although fewer than 1% of children suffer from onychomycosis, the proportion increases with age; more than a third of adults older than 70 years have the disease. In children who are not severely affected, the disease can go untreated.

There is no approved treatment for onychomycosis in children, but Dr. Eichenfield said that he is comfortable recommending terbinafine as long as parents are informed that this is an off-label use of the drug. “Terbinafine is so cost effective,” he said. “You can get it for $4-$7 per month. It used to be $1,200 for a full course.”

His recommended dosages to treat onychomycosis are the following:

▸ For children weighing less than 20 kg: 62.5 mg/day.

▸ For children weighing 20-40 kg: 125 mg/day.

▸ For children weighing more than 40 kg: 250 mg/day.

“It's recommended that you get baseline lab work,” he said. “Many of us will repeat [it] 1 month into the therapy.”

Dr. Eichenfield reported having no relevant conflicts of interest.

Topical medications alone seldom cure tinea capitis, but they can be used in combination with systemic drugs.

Source DR. EICHENFIELD

Recommended Reading

HIV Testing Rates Reached Record Level in 2009
MDedge Family Medicine
Daily Antiretroviral Prophylaxis Cut Risk of HIV Infection
MDedge Family Medicine
Hepatitis C Vaccine Boosted Immune Response
MDedge Family Medicine
Otitis Research Supports New AAP Guidelines
MDedge Family Medicine
Use of Antibiotics for Acute Otitis Media Tx Gets a Boost
MDedge Family Medicine
Parental Diagnosis of AOM Appears to Be Unreliable
MDedge Family Medicine
Bedside Tool May Predict C. difficile Outcomes
MDedge Family Medicine
Fecal Transplantation an Option for Recurrent C. difficile
MDedge Family Medicine
Telaprevir, Boceprevir Improved HCV Cure Rates
MDedge Family Medicine
Pneumococcal Vaccine: Beyond 13 Serotypes
MDedge Family Medicine